![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial
|
|
|
Reported by Jules Levin
48th Annual Meeting of the
European Association for the Study of the Liver
24 April - 28 April 2013 · Amsterdam, The Netherlands
Ira Jacobson,1 Gregory J Dore,2 Graham R Foster,3 Michael W Fried,4 Monica Radu,5 Vladimir V Rafalskiy,6 larysa Moroz,7 antonio Craxì,8 Monika Peeters,9 Oliver lenz,9 sivi Ouwerkerk-Mahadevan,10 Ronald Kalmeijer,11 Maria Beumont-Mauviel9
1Weill Cornell Medical College, New York, NY, USA; 2Kirby Institute, University of New South Wales, Sydney, Australia; 3Queen Mary University of London, Barts Health, London, UK; 4University of North Carolina at Chapel Hill, NC, USA; 5Institutul de Boli infectioase, Bucharest, Romania; 6Smolensk Regional Clinical Hospital, Smolensk Oblast, Russia; 7Vinnytsia National Medical University, Vinnytsia, Ukraine; 8Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy; 9Janssen Infectious Diseases BVBA, Beerse, Belgium; 10Jansssen Research & Development, Beerse, Belgium; 11Janssen Global Services, LLC, Titusville, NJ, USA
![EASL1.gif](../images/042513/042513-1/EASL1.gif)
![EASL2.gif](../images/042513/042513-1/EASL2.gif)
![EASL3.gif](../images/042513/042513-1/EASL3.gif)
![EASL4.gif](../images/042513/042513-1/EASL4.gif)
![EASL5.gif](../images/042513/042513-1/EASL5.gif)
![EASL6.gif](../images/042513/042513-1/EASL6.gif)
![Figure6.gif](../images/042513/042513-1/Figure6.gif)
![EASL7.gif](../images/042513/042513-1/EASL7.gif)
![EASL8.gif](../images/042513/042513-1/EASL8.gif)
![EASL9.gif](../images/042513/042513-1/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|